GlassScriptPhysician profile
Tom A Christensen
NPI 1164429825
$12,253.92
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,768 · 2020: $3,098 · 2021: $4,077 · 2022: $1,263 · 2023: $48.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $48.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $48.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,329.02 | 2019-2022 | |
| Novo Nordisk INC | $1,016.55 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,015.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,000.87 | 2019-2022 | |
| Amarin Pharma, INC. | $990.39 | 2019-2022 | |
| Amgen INC. | $947.24 | 2019-2022 | |
| Astellas Pharma US INC | $923.24 | 2019-2022 | |
| Lilly USA, LLC | $528.38 | 2020-2022 | |
| Abbvie INC. | $470.66 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.51 | 2019-2022 | |
| Pfizer INC. | $398.41 | 2019-2021 | |
| Allergan, INC. | $377.11 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $269.84 | 2019-2022 | |
| Mylan Specialty L.P. | $245.43 | 2019-2022 |
Show all 45 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.